Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of AMG
337 in patients who have MET amplified gastric, gastroesophageal junction or esophageal
adenocarcinoma or other MET amplified solid tumors. The study is designed to estimate the
objective response rate of AMG 337 by tumor type.